Providing a cellular-based approach for treating hair loss, RepliCel currently has three project developments that centre on applying cell therapy technology to offer skin rejuvenation, tendon regeneration and hair growth solutions.
At present, RepliCel is working in partnership with Japanese personal care player, Shiseido, to develop a product for hair loss.
"The Asian market has the world’s highest demand for hair loss treatments,” highlighted Lee Buckler, President and CEO, RepliCel Life Sciences.
“We believe the product in development to treat Androgenetic Alopecia represents one of the most innovative and promising breakthroughs for this market in the past 20 years,” Buckler added.
Drawing upon consumer demand for natural and non-invasive procedures in APAC that effectively help to overcome the visible signs of getting older, RepliCel expects its “cell therapy injectables to reverse the impacts of hair loss and ageing/damaged skin in a natural and non-surgical way using the patient’s own cells,” Buckler went on to say.
Originally named Tricho Science when it launched in 2006, the company underwent a rebrand in 2010 to become RepliCel Life Sciences.
Focusing on its R&D efforts since 2003, RepliCel has now gathered up to five years of safety data surrounding its skin and hair care-based portfolio.
As its product range evolves, the company is now investing in designing and pursuing further studies to demonstrate efficacy.
Initially, RepliCel’s original science evolved out of hair loss research that studied the cells of the hair follicle. This research then led to the development of its androgenic alopecia treatment solution.
Through studying hair follicle cells, RepliCel identified an additional cell population, highly expressive of type 1 collagen and other tissue building proteins, which it is currently developing for skin rejuvenation.
The second part of our article with Lee Buckler, President and CEO, RepliCel Life Sciences, which focuses on the science behind the new cell therapy applications, will be published on Wednesday 17th May 2017.